

DR. REDDY'S LABORATORIES LTD.

8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500034. Telangana, India.

CONTACT

INVESTOR RELATIONS	MEDIA RELATIONS
KEDAR UPADHYE kedar@drreddys.com (Ph: +91-40-66834297)	CALVIN PRINTER calvinprinter@drreddys.com (Ph: +91-40- 49002121)

Dr. Reddy's to release Q3FY16 results on Feb 9, 2016 // Earnings call slated for Feb 9, 6.30 PM IST / 8.00 AM EST

Hyderabad, India, January 28, 2016

Dr. Reddy's Laboratories (NYSE: RDY; NSE: DRREDDY; BSE: 500124) will announce results for the Third Quarter and 9 months ended December 31, 2015 on Tuesday, February 9, 2016 after the Board Meeting. The results will be available on the Company's website www.drreddys.com

Summary of Events

Event	Date and Time	Medium
Release of financial results	February 9th, after the Board Meeting	Email, Media, Company website, Businesswire
Earnings Call	February 9th, 6.30 PM IST / 8:00 AM EST	Hosted by the Company (Details below)
Webcast of Earnings Call	February 9th, 6.30 PM IST / 8.00 AM EST through Feb 13 th	URL available on Company's website, www.drreddys.com
Transcript of the Earnings call	Will be available on the Company's website	URL available on Company's website, www.drreddys.com

Earnings Call

Following the release, the management of the Company will host an earnings call to discuss the Company's financial performance. *(Dial In and other details given below)*

Audio Webcast

The audio webcast of the earnings call will be available to all interested parties at www.drreddys.com. Please visit the web site at least fifteen minutes ahead of the scheduled start time to register and to download and install any necessary audio software. Participants in the webcast can listen to the proceedings, but will not be able to ask questions. The replay will be available 2 hours after the earnings call, through February 13, 2016. For play back dial in phone No: 022 3065 2322, 022 61813322 and ID: 375#.

Transcript

The transcript of the earnings call will also be available on the Company's website

Conference Dial-In Numbers	
Primary Number:	+91 22 3960 0616
Secondary Number:	+91 22 6746 5826
<i>The numbers listed above are universally accessible from all networks and all countries.</i>	
Local Access Number:	6000 1221 Available in - Ahmedabad, Bangalore, Bhubaneswar, Chandigarh, Chennai, Coimbatore, Delhi, Goa, Guntur, Gurgaon, Hyderabad, Indore, Jamshedpur, Kanpur, Kochi/Cochin, Kolhapur, Kolkata, Nagpur, Noida, Patna, Pune, Raipur, Rajkot, Surat, Trivandrum, Vadodara, Vijayawada <i>Accessible from all major carriers except BSNL/MTNL.</i> 3940 3977 Available in - Ahmedabad, Bangalore, Chandigarh, Chennai, Gurgaon (NCR), Hyderabad, Kochi/Cochin, Kolkata, Lucknow, Pune <i>Accessible from all carriers.</i>
International Toll Free Number:	USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448

No password/pin number is necessary to dial in to any of the other calls. As participation in the call is limited, early registration is encouraged. The operator will provide instructions on asking questions before and during the call...

.....
About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (NYSE: RDY NSE: DRREDDY; BSE: 500124) is an integrated pharmaceutical company, committed to accelerating access to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infectives. Dr. Reddy's operates in markets across the globe. Our major markets include – USA, Russia & CIS, Venezuela and India. For more information, log on to: www.drreddys.com

.....
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues.

The company assumes no obligation to update any information contained herein.